Patients' views of interferon therapy in MS.
Interferon beta-1b is a new and somewhat controversial drug therapy used in the management of MS. In this study people using interferon beta-1b reported fewer relapses, less use of their primary health-care services and an overall improvement in their condition. Outcome measures for use in MS need to be more sensitive in order to measure effectively the impact of therapies such as interferon beta-1b and beta-1a. Further research using validated quality-of-life scales to fully assess the impact of these new treatments is urgently needed.
Burgess
M
M
Salford Royal Hospitals NHS Trust, Manchester.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D001294:Attitude to Health; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000523:psychology*; D010865:Pilot Projects; D011788:Quality of Life; D011795:Surveys and Questionnaires
D000276:Adjuvants, Immunologic; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a